Christoph Meyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christoph Meyer has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Peter Vermathen
Magnetic Resonance Methodology, Institute of Diagnostic and Interventional Neuroradiology University of Bern Bern Switzerland
3 shared publications - Steven Dooley
Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
3 shared publications - Christian Urzì
Magnetic Resonance Methodology, Institute of Diagnostic and Interventional Neuroradiology University of Bern Bern Switzerland
2 shared publications - Damian Hertig
Magnetic Resonance Methodology, Institute of Diagnostic and Interventional Neuroradiology University of Bern Bern Switzerland
2 shared publications - Jean-Marc Nuoffer
University Institute of Clinical Chemistry, Bern University Hospital, Bern, Switzerland
2 shared publications - Peter Rene Mertens
University Clinic for Nephrology and Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
2 shared publications
Latest Publications
- Open Access
- 4 September 2024
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 48 (1)
Intra‐ and extracellular real‐time analysis of perfused fibroblasts using an NMR bioreactor: A pilot study
Introduction: Metabolomic discrimination of different mitochondrial defects is challenging. We describe an NMR‐based bioreactor allowing real‐time intra‐ and extracellular metabolic investigation of perfused fibroblasts.Objectives: The objective of this study is (I) determining whether metabolic investigations of perfused fibroblasts overall and separated for intra‐ and extracellular contributions by real‐time NMR allows for discrimination of different representative mitochondrial defects in a feasibility study and (II) gaining insight into physiological consequences of mitochondrial dysfunction in basal condition and during glycolysis inhibition.Methods: Overall, intra‐ and extracellular metabolomes of malate dehydrogenase 2 (MDH2), pyruvate dehydrogenase (PDH), complex I (CI) deficient fibroblasts, and control fibroblasts were investigated under standard culture conditions and under glycolysis inhibition. In addition to “overall” metabolite quantification, intra‐ and extracellular metabolic contributions were separated based on diffusion rate differences.Results and Discussion: Overall metabolites: Chemometric analysis of the entire metabolome revealed good separation between control, PDH and MDH2, while CI was less well separated. However, mixed intra‐ and extracellular changes complicated interpretation of the cellular metabolism. Intra‐ and extracellular metabolites: Compartment specific chemometrics revealed possibly augmenting metabolomic separation between control and deficient cell lines under basal and inhibition condition. All mitochondrial defects exhibited upregulation of glycolytic metabolism compared to controls. Inhibition of glycolysis resulted in perturbations of other metabolic pathways such as glutaminolysis, alanine, arginine, glutamate, and proline metabolism. MDH2 showed upregulation of alanine and glutamate metabolism, while the CI defect revealed lower intracellular arginine and downregulation of glutamate and arginine‐dependent proline synthesis.Conclusion: Discrimination of intra‐ and extracellular metabolic contributions helps understanding the underlying mechanisms of mitochondrial disorders, uncovers potential metabolic biomarkers, and unravels metabolic pathway‐specific adaptations in response to metabolic perturbations.
- 4 September 2024
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 48 (1)
Open AccessIntra‐ and extracellular real‐time analysis of perfused fibroblasts using an NMR bioreactor: A pilot study
Introduction: Metabolomic discrimination of different mitochondrial defects is challenging. We describe an NMR‐based bioreactor allowing real‐time intra‐ and extracellular metabolic investigation of perfused fibroblasts.Objectives: The objective of this study is (I) determining whether metabolic investigations of perfused fibroblasts overall and separated for intra‐ and extracellular contributions by real‐time NMR allows for discrimination of different representative mitochondrial defects in a feasibility study and (II) gaining insight into physiological consequences of mitochondrial dysfunction in basal condition and during glycolysis inhibition.Methods: Overall, intra‐ and extracellular metabolomes of malate dehydrogenase 2 (MDH2), pyruvate dehydrogenase (PDH), complex I (CI) deficient fibroblasts, and control fibroblasts were investigated under standard culture conditions and under glycolysis inhibition. In addition to “overall” metabolite quantification, intra‐ and extracellular metabolic contributions were separated based on diffusion rate differences.Results and Discussion: Overall metabolites: Chemometric analysis of the entire metabolome revealed good separation between control, PDH and MDH2, while CI was less well separated. However, mixed intra‐ and extracellular changes complicated interpretation of the cellular metabolism. Intra‐ and extracellular metabolites: Compartment specific chemometrics revealed possibly augmenting metabolomic separation between control and deficient cell lines under basal and inhibition condition. All mitochondrial defects exhibited upregulation of glycolytic metabolism compared to controls. Inhibition of glycolysis resulted in perturbations of other metabolic pathways such as glutaminolysis, alanine, arginine, glutamate, and proline metabolism. MDH2 showed upregulation of alanine and glutamate metabolism, while the CI defect revealed lower intracellular arginine and downregulation of glutamate and arginine‐dependent proline synthesis.Conclusion: Discrimination of intra‐ and extracellular metabolic contributions helps understanding the underlying mechanisms of mitochondrial disorders, uncovers potential metabolic biomarkers, and unravels metabolic pathway‐specific adaptations in response to metabolic perturbations.
- Open Access
- 12 December 2023
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (2) , 270-279
Complex I, V, and MDH2 deficient human skin fibroblasts reveal distinct metabolic signatures by 1H HR‐MAS NMR
In this study, we investigated the metabolic signatures of different mitochondrial defects (two different complex I and complex V, and the one MDH2 defect) in human skin fibroblasts (HSF). We hypothesized that using a selective culture medium would cause defect specific adaptation of the metabolome and further our understanding of the biochemical implications for the studied defects. All cells were cultivated under galactose stress condition and compared to glucose‐based cell culture condition. We investigated the bioenergetic profile using Seahorse XFe96 cell analyzer and assessed the extracellular metabolic footprints and the intracellular metabolic fingerprints using NMR. The galactose‐based culture condition forced a bioenergetic switch from a glycolytic to an oxidative state in all cell lines which improved overall separation of controls from the different defect groups. The extracellular metabolome was discriminative for separating controls from defects but not the specific defects, whereas the intracellular metabolome suggests CI and CV changes and revealed clear MDH2 defect‐specific changes in metabolites associated with the TCA cycle, malate aspartate shuttle, and the choline metabolism, which are pronounced under galactose condition.
- 12 December 2023
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (2) , 270-279
Open AccessComplex I, V, and MDH2 deficient human skin fibroblasts reveal distinct metabolic signatures by 1H HR‐MAS NMR
In this study, we investigated the metabolic signatures of different mitochondrial defects (two different complex I and complex V, and the one MDH2 defect) in human skin fibroblasts (HSF). We hypothesized that using a selective culture medium would cause defect specific adaptation of the metabolome and further our understanding of the biochemical implications for the studied defects. All cells were cultivated under galactose stress condition and compared to glucose‐based cell culture condition. We investigated the bioenergetic profile using Seahorse XFe96 cell analyzer and assessed the extracellular metabolic footprints and the intracellular metabolic fingerprints using NMR. The galactose‐based culture condition forced a bioenergetic switch from a glycolytic to an oxidative state in all cell lines which improved overall separation of controls from the different defect groups. The extracellular metabolome was discriminative for separating controls from defects but not the specific defects, whereas the intracellular metabolome suggests CI and CV changes and revealed clear MDH2 defect‐specific changes in metabolites associated with the TCA cycle, malate aspartate shuttle, and the choline metabolism, which are pronounced under galactose condition.
- 1 July 2016
- Published by Elsevier in The American Journal of Pathology
- Vol. 186 (7) , 1874-1889
Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression
- 1 July 2016
- Published by Elsevier in The American Journal of Pathology
- Vol. 186 (7) , 1874-1889
Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression
- Open Access
- 17 March 2015
- Published by Portland Press Ltd. in Clinical Science
- Vol. 128 (11) , 761-774
Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma
Transforming growth factor β (TGF-β) is cytostatic towards damage-induced compensatory hepatocyte proliferation. This function is frequently lost during hepatocarcinogenesis, thereby switching the TGF-β role from tumour suppressor to tumour promoter. In the present study, we investigate Smad7 overexpression as a pathophysiological mechanism for cytostatic TGF-β inhibition in liver damage and hepatocellular carcinoma (HCC). Transgenic hepatocyte-specific Smad7 overexpression in damaged liver of fumarylacetoacetate hydrolase (FAH)-deficient mice increased compensatory proliferation of hepatocytes. Similarly, modulation of Smad7 expression changed the sensitivity of Huh7, FLC-4, HLE and HLF HCC cell lines for cytostatic TGF-β effects. In our cohort of 140 HCC patients, Smad7 transcripts were elevated in 41.4% of HCC samples as compared with adjacent tissue, with significant positive correlation to tumour size, whereas low Smad7 expression levels were significantly associated with worse clinical outcome. Univariate and multivariate analyses indicate Smad7 levels as an independent predictor for overall (PP=0.0123). Delineating a mechanism for Smad7 transcriptional regulation in HCC, we identified cold-shock Y-box protein-1 (YB-1), a multifunctional transcription factor. YB-1 RNAi reduced TGF-β-induced and endogenous Smad7 expression in Huh7 and FLC-4 cells respectively. YB-1 and Smad7 mRNA expression levels correlated positively (P<0.0001). Furthermore, nuclear co-localization of Smad7 and YB-1 proteins was present in cancer cells of those patients. In summary, the present study provides a YB-1/Smad7-mediated mechanism that interferes with anti-proliferative/tumour-suppressive TGF-β actions in a subgroup of HCC cells that may facilitate aspects of tumour progression.
- 17 March 2015
- Published by Portland Press Ltd. in Clinical Science
- Vol. 128 (11) , 761-774
Open AccessSmad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma
Transforming growth factor β (TGF-β) is cytostatic towards damage-induced compensatory hepatocyte proliferation. This function is frequently lost during hepatocarcinogenesis, thereby switching the TGF-β role from tumour suppressor to tumour promoter. In the present study, we investigate Smad7 overexpression as a pathophysiological mechanism for cytostatic TGF-β inhibition in liver damage and hepatocellular carcinoma (HCC). Transgenic hepatocyte-specific Smad7 overexpression in damaged liver of fumarylacetoacetate hydrolase (FAH)-deficient mice increased compensatory proliferation of hepatocytes. Similarly, modulation of Smad7 expression changed the sensitivity of Huh7, FLC-4, HLE and HLF HCC cell lines for cytostatic TGF-β effects. In our cohort of 140 HCC patients, Smad7 transcripts were elevated in 41.4% of HCC samples as compared with adjacent tissue, with significant positive correlation to tumour size, whereas low Smad7 expression levels were significantly associated with worse clinical outcome. Univariate and multivariate analyses indicate Smad7 levels as an independent predictor for overall (PP=0.0123). Delineating a mechanism for Smad7 transcriptional regulation in HCC, we identified cold-shock Y-box protein-1 (YB-1), a multifunctional transcription factor. YB-1 RNAi reduced TGF-β-induced and endogenous Smad7 expression in Huh7 and FLC-4 cells respectively. YB-1 and Smad7 mRNA expression levels correlated positively (P<0.0001). Furthermore, nuclear co-localization of Smad7 and YB-1 proteins was present in cancer cells of those patients. In summary, the present study provides a YB-1/Smad7-mediated mechanism that interferes with anti-proliferative/tumour-suppressive TGF-β actions in a subgroup of HCC cells that may facilitate aspects of tumour progression.
- 9 January 2012
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 50 (01) , P1_27
Dll4 plays a critical role in HBV-associated liver fibrogenesis
Background & Aims: Notch signaling is crucial in the development of metazoans, determining cell fate, and is directly linked to multiple human organ disorders. In human, 5 Notch ligands (Jagged–1, Jagged–2, Delta–1, Delta–3 and Delta–4) and 4 receptors (Notch–1, Notch–2, Notch–3 and Notch–4) have been identified. Mutation of Jagged–1 gene leads to Alagille syndrome. However, patients with Alagille syndrome usually do not progress into serious liver fibrosis. In the present study, we investigated the role of Notch ligands in HBV associated liver fibrogenesis. Methods: The expression of Notch ligands, including Jagged1, Jagged2, Delta-like ligand (Dll)1, Dll3 and Dll4, was measured in 130 patients with chronic HBV infection by immunohistochemistry. The effect of Notch ligands was as well examined in TGF-β treated hepatic stellate cells (HSCs). Results: Immunohistochemistry analysis revealed positive expression of Jagged1, Dll3 and Dll4 in fibrotic liver tissues from chronic HBV infected patients. Distinct from Jagged1 and Dll3, which are mainly found in cholangiocytes and hepatocytes, sinusoidal cells and portal tracts were positive for Dll4. Confocol microscopy analysis confirmed these Dll4-positive cells were α-smooth muscle actin (α-SMA) positive, indicating that Dll4 was upregulated in activated HSCs or myofibroblasts in chronic HBV infected patients. Dll4 positive liver cells remarkably correlated with inflammatory grade (r=0.6, PConclusions: Dll4 plays a crucial role in liver fibrogenesis via influencing TGF-β dependent activation of HSCs and extracelluar matrix production.
- 9 January 2012
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 50 (01) , P1_27
Dll4 plays a critical role in HBV-associated liver fibrogenesis
Background & Aims: Notch signaling is crucial in the development of metazoans, determining cell fate, and is directly linked to multiple human organ disorders. In human, 5 Notch ligands (Jagged–1, Jagged–2, Delta–1, Delta–3 and Delta–4) and 4 receptors (Notch–1, Notch–2, Notch–3 and Notch–4) have been identified. Mutation of Jagged–1 gene leads to Alagille syndrome. However, patients with Alagille syndrome usually do not progress into serious liver fibrosis. In the present study, we investigated the role of Notch ligands in HBV associated liver fibrogenesis. Methods: The expression of Notch ligands, including Jagged1, Jagged2, Delta-like ligand (Dll)1, Dll3 and Dll4, was measured in 130 patients with chronic HBV infection by immunohistochemistry. The effect of Notch ligands was as well examined in TGF-β treated hepatic stellate cells (HSCs). Results: Immunohistochemistry analysis revealed positive expression of Jagged1, Dll3 and Dll4 in fibrotic liver tissues from chronic HBV infected patients. Distinct from Jagged1 and Dll3, which are mainly found in cholangiocytes and hepatocytes, sinusoidal cells and portal tracts were positive for Dll4. Confocol microscopy analysis confirmed these Dll4-positive cells were α-smooth muscle actin (α-SMA) positive, indicating that Dll4 was upregulated in activated HSCs or myofibroblasts in chronic HBV infected patients. Dll4 positive liver cells remarkably correlated with inflammatory grade (r=0.6, PConclusions: Dll4 plays a crucial role in liver fibrogenesis via influencing TGF-β dependent activation of HSCs and extracelluar matrix production.
- Open Access
- 1 November 2010
- Published by Swiss Chemical Society in Chimia
- Vol. 64 (11) , 825
Enhancing the Quality and Efficiency of Analytical Method Development as Part of the Quality by Design Framework
- 1 November 2010
- Published by Swiss Chemical Society in Chimia
- Vol. 64 (11) , 825
Open AccessEnhancing the Quality and Efficiency of Analytical Method Development as Part of the Quality by Design Framework
- Open Access
- 1 June 2010
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 25 (3) , 279-287
Potential of Optimal Preloading in Anti-CD20 Antibody Radioimmunotherapy: An Investigation Based on Pharmacokinetic Modeling
Recently, it has been suggested that the concept of preloading is limited by using a standard amount of unlabeled antibody. To identify the potential of optimal preloading, a pharmacokinetic model that describes the biodistribution of anti-CD20 antibody was developed. Simulations were conducted for different tumor burdens, spleen sizes, and tumor permeabilities. The optimal amount of unlabeled antibody was determined for each scenario. These simulations show that the currently administered standard amount is not optimal. A preload of 150 mg or lower would result in equal or higher tumor uptake in all cases. For tumors with high permeability, the uptake of labeled antibody could be increased by a factor of 8.5 using the considerably reduced optimal preload. The most sensitive parameter for the choice of the optimal amount of unlabeled antibody is the tumor uptake index. The results indicate that a personalized approach for radioimmunotherapy (RIT) with anti-CD20 antibody is required to account for the interpatient variability. The optimal amount of unlabeled antibody, which has to be determined by using a pharmacokinetic model, could substantially improve tumor uptake and thus RIT with anti-CD20 antibody.
- 1 June 2010
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 25 (3) , 279-287
Open AccessPotential of Optimal Preloading in Anti-CD20 Antibody Radioimmunotherapy: An Investigation Based on Pharmacokinetic Modeling
Recently, it has been suggested that the concept of preloading is limited by using a standard amount of unlabeled antibody. To identify the potential of optimal preloading, a pharmacokinetic model that describes the biodistribution of anti-CD20 antibody was developed. Simulations were conducted for different tumor burdens, spleen sizes, and tumor permeabilities. The optimal amount of unlabeled antibody was determined for each scenario. These simulations show that the currently administered standard amount is not optimal. A preload of 150 mg or lower would result in equal or higher tumor uptake in all cases. For tumors with high permeability, the uptake of labeled antibody could be increased by a factor of 8.5 using the considerably reduced optimal preload. The most sensitive parameter for the choice of the optimal amount of unlabeled antibody is the tumor uptake index. The results indicate that a personalized approach for radioimmunotherapy (RIT) with anti-CD20 antibody is required to account for the interpatient variability. The optimal amount of unlabeled antibody, which has to be determined by using a pharmacokinetic model, could substantially improve tumor uptake and thus RIT with anti-CD20 antibody.
- 5 October 2007
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 79 (21) , 8323-8326
Monitoring the Interactions of Tocopherol Homologues with Reversed-Phase Stationary HPLC Phases by 1H Suspended-State Saturation Transfer Difference High-Resolution/Magic Angle Spinning NMR Spectroscopy
The separation process in reversed-phase high-performance liquid chromatography employing C18 phases is mainly due to hydrophobic interactions. The separation of tocopherol isomers, exhibited by the C30 phases, however, is additionally driven by shape selectivity. This phenomenon is investigated by suspended-state nuclear magnetic resonance spectroscopy using the saturation transfer difference technique, which was originally introduced to study protein−ligand interactions. The interaction strength between β-/γ-tocopherol and three different stationary phases was estimated qualitatively. The nuclear magnetic resonance data are compared to chromatographic data, and a similar mode of interaction between the analytes and the stationary phases is elucidated.
- 5 October 2007
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 79 (21) , 8323-8326
Monitoring the Interactions of Tocopherol Homologues with Reversed-Phase Stationary HPLC Phases by 1H Suspended-State Saturation Transfer Difference High-Resolution/Magic Angle Spinning NMR Spectroscopy
The separation process in reversed-phase high-performance liquid chromatography employing C18 phases is mainly due to hydrophobic interactions. The separation of tocopherol isomers, exhibited by the C30 phases, however, is additionally driven by shape selectivity. This phenomenon is investigated by suspended-state nuclear magnetic resonance spectroscopy using the saturation transfer difference technique, which was originally introduced to study protein−ligand interactions. The interaction strength between β-/γ-tocopherol and three different stationary phases was estimated qualitatively. The nuclear magnetic resonance data are compared to chromatographic data, and a similar mode of interaction between the analytes and the stationary phases is elucidated.